Salivary Antioxidant Capacity in Graft versus Host Disease

Author： Nagler Rafael Barness-Hadar Liat Lieba Merav Nagler Arnon

ISSN： 0735-7907

Source： Cancer Investigation, Vol.24, Iss.3, 2006-05, pp. : 269-277

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Transfusion-associated graft-versus-host disease: an update

By Dal-Pont Christian Schennach Harald

memo - Magazine of European Medical Oncology, Vol. 6, Iss. 4, 2013-12 ,pp. : 254-257

Springer Publishing Company

Access to resources Recommend Favorite

Standardizing chronic graft-versus-host disease

By van Besien Koen

Future Oncology, Vol. 2, Iss. 4, 2006-08 ,pp. : 459-462

Future Medicine

Access to resources Recommend Favorite

Targeting CD83 for the treatment of graft-versus-host disease (Review)

By Wang Xiongfei Wei Ming Q. Liu Xiaosong

Experimental and Therapeutic Medicine, Vol. 5, Iss. 6, 2013-06 ,pp. : 1545-1550

Spandidos Publications

Access to resources Recommend Favorite

Graft versus host disease following liver transplantation: A case report

Experimental and Therapeutic Medicine, Vol. 8, Iss. 4, 2014-01 ,pp. : 1164-1166

Spandidos Publications

Access to resources Recommend Favorite

Suppression of graft-versus-host disease and retention of graft-versus-tumour reaction by murine genetically engineered dendritic cells following bone marrow transplantation

Molecular Medicine Reports, Vol. 11, Iss. 5, 2015-01 ,pp. : 3820-3827

Spandidos Publications

Access to resources Recommend Favorite